Elisa Pin1, David Just1, Caroline Lindblad2, Faiez Al Nimer3,4, Peter Nilsson1, Bo-Michael Bellander3,5, Mikael Svensson3,5, Fredrik Piehl3,4, Eric Peter Thelin3,6. 1. Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH-Royal Institute of Technology, Stockholm, Sweden. 2. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. caroline.lindblad@ki.se. 3. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. 4. Center for Neurology, Academic Specialist Center, Stockholm Health Services, Stockholm, Sweden. 5. Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden. 6. Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
Abstract
BACKGROUND: Severe traumatic brain injury (TBI) is associated with blood-brain barrier (BBB) disruption and a subsequent neuroinflammatory process. We aimed to perform a multiplex screening of brain enriched and inflammatory proteins in blood and cerebrospinal fluid (CSF) in order to study their role in BBB disruption, neuroinflammation and long-term functional outcome in TBI patients and healthy controls. METHODS: We conducted a prospective, observational study on 90 severe TBI patients and 15 control subjects. Clinical outcome data, Glasgow Outcome Score, was collected after 6-12 months. We utilized a suspension bead antibody array analyzed on a FlexMap 3D Luminex platform to characterize 177 unique proteins in matched CSF and serum samples. In addition, we assessed BBB disruption using the CSF-serum albumin quotient (QA), and performed Apolipoprotein E-genotyping as the latter has been linked to BBB function in the absence of trauma. We employed pathway-, cluster-, and proportional odds regression analyses. Key findings were validated in blood samples from an independent TBI cohort. RESULTS: TBI patients had an upregulation of structural CNS and neuroinflammatory pathways in both CSF and serum. In total, 114 proteins correlated with QA, among which the top-correlated proteins were complement proteins. A cluster analysis revealed protein levels to be strongly associated with BBB integrity, but not carriage of the Apolipoprotein E4-variant. Among cluster-derived proteins, innate immune pathways were upregulated. Forty unique proteins emanated as novel independent predictors of clinical outcome, that individually explained ~ 10% additional model variance. Among proteins significantly different between TBI patients with intact or disrupted BBB, complement C9 in CSF (p = 0.014, ΔR2 = 7.4%) and complement factor B in serum (p = 0.003, ΔR2 = 9.2%) were independent outcome predictors also following step-down modelling. CONCLUSIONS: This represents the largest concomitant CSF and serum proteomic profiling study so far reported in TBI, providing substantial support to the notion that neuroinflammatory markers, including complement activation, predicts BBB disruption and long-term outcome. Individual proteins identified here could potentially serve to refine current biomarker modelling or represent novel treatment targets in severe TBI.
BACKGROUND: Severe traumatic brain injury (TBI) is associated with blood-brain barrier (BBB) disruption and a subsequent neuroinflammatory process. We aimed to perform a multiplex screening of brain enriched and inflammatory proteins in blood and cerebrospinal fluid (CSF) in order to study their role in BBB disruption, neuroinflammation and long-term functional outcome in TBI patients and healthy controls. METHODS: We conducted a prospective, observational study on 90 severe TBI patients and 15 control subjects. Clinical outcome data, Glasgow Outcome Score, was collected after 6-12 months. We utilized a suspension bead antibody array analyzed on a FlexMap 3D Luminex platform to characterize 177 unique proteins in matched CSF and serum samples. In addition, we assessed BBB disruption using the CSF-serum albumin quotient (QA), and performed Apolipoprotein E-genotyping as the latter has been linked to BBB function in the absence of trauma. We employed pathway-, cluster-, and proportional odds regression analyses. Key findings were validated in blood samples from an independent TBI cohort. RESULTS: TBI patients had an upregulation of structural CNS and neuroinflammatory pathways in both CSF and serum. In total, 114 proteins correlated with QA, among which the top-correlated proteins were complement proteins. A cluster analysis revealed protein levels to be strongly associated with BBB integrity, but not carriage of the Apolipoprotein E4-variant. Among cluster-derived proteins, innate immune pathways were upregulated. Forty unique proteins emanated as novel independent predictors of clinical outcome, that individually explained ~ 10% additional model variance. Among proteins significantly different between TBI patients with intact or disrupted BBB, complement C9 in CSF (p = 0.014, ΔR2 = 7.4%) and complement factor B in serum (p = 0.003, ΔR2 = 9.2%) were independent outcome predictors also following step-down modelling. CONCLUSIONS: This represents the largest concomitant CSF and serum proteomic profiling study so far reported in TBI, providing substantial support to the notion that neuroinflammatory markers, including complement activation, predicts BBB disruption and long-term outcome. Individual proteins identified here could potentially serve to refine current biomarker modelling or represent novel treatment targets in severe TBI.
Authors: Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén Journal: Science Date: 2015-01-23 Impact factor: 47.728
Authors: Marcus O D Sjödin; Jonas Bergquist; Magnus Wetterhall Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2010-05-31 Impact factor: 3.205
Authors: Adel Helmy; Keri L H Carpenter; David K Menon; John D Pickard; Peter J A Hutchinson Journal: J Cereb Blood Flow Metab Date: 2010-08-18 Impact factor: 6.200
Authors: Sandra D W Buttram; Stephen R Wisniewski; Edwin K Jackson; P David Adelson; Keri Feldman; Hülya Bayir; Rachel P Berger; Robert S B Clark; Patrick M Kochanek Journal: J Neurotrauma Date: 2007-11 Impact factor: 5.269
Authors: Eric Thelin; Faiez Al Nimer; Arvid Frostell; Henrik Zetterberg; Kaj Blennow; Harriet Nyström; Mikael Svensson; Bo-Michael Bellander; Fredrik Piehl; David W Nelson Journal: J Neurotrauma Date: 2019-06-19 Impact factor: 5.269
Authors: Kristin Leifsdottir; Kerstin Jost; Veronica Siljehav; Eric P Thelin; Philipp Lassarén; Peter Nilsson; Ásgeir Haraldsson; Staffan Eksborg; Eric Herlenius Journal: Front Pediatr Date: 2022-07-19 Impact factor: 3.569
Authors: Adel Helmy; Eric Peter Thelin; Philipp Lassarén; Caroline Lindblad; Arvid Frostell; Keri L H Carpenter; Mathew R Guilfoyle; Peter J A Hutchinson Journal: J Neuroinflammation Date: 2021-09-25 Impact factor: 8.322
Authors: Kristin Leifsdottir; Eric P Thelin; Philipp Lassarén; Veronica Siljehav; Peter Nilsson; Staffan Eksborg; Eric Herlenius Journal: Acta Paediatr Date: 2022-02-17 Impact factor: 4.056